Angel S. Angelov was named Chief Medical Officer of Vistagen Therapeutics, Inc. As of November 6, 2026, Vistagen Therapeutics, Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 19, 2026 to July 31, 2026, naming 1 appointment (Form 8-K, May 19, 2026).
Who owns Vistagen Therapeutics, Inc.?
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Vistagen Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-07-31
- · In / out: Reported · Person: not named in the filing · 8-K, 2026-06-17
- · In / out: In · Person: Angel S. Angelov · Role: Chief Medical Officer · 8-K, 2026-05-19
Vistagen Therapeutics, Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-19 to 2026-07-31. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Vistagen Therapeutics, Inc. files it.
Layoffs on record: 1 filing or notice, latest 2026-10-30 (layoff filings and notices).
Also on the record for Vistagen Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Stake report, Schedule 13G/A, by Chen Yu | 6.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 9.9% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by ORBIMED ADVISORS LLC | — | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Chen Yu | 9.99% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | 9.9% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Great Point Partners, LLC | 4.95% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by ORBIMED CAPITAL LLC | 4.2% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by StemPoint Capital LP | 1.5% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Nantahala Capital Management, LLC | 4.71% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.62% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by ORBIMED CAPITAL LLC | 5.34% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Vistagen Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Vistagen Therapeutics, Inc. and the records around it.
Vistagen Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- StemPoint Capital LP also filed stake reports on 4 other companies: Cellectar Biosciences, Inc. (Aug 2026), Faeth Therapeutics, Inc. (Aug 2026), Surrozen, Inc. (Aug 2026)
- TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Abivax SA (Aug 2026), Entrada Therapeutics, Inc. (Aug 2026), Savara Inc. (Feb 2026)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
Watch Vistagen Therapeutics, Inc.
Get an email when Vistagen Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vistagen Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Vistagen Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vistagen Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 17 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-31 | Reported | not named in the filing | 8-K, 2026-07-31 | ||
| 2026-06-17 | Reported | not named in the filing | 8-K, 2026-06-17 | ||
| 2026-05-19 | In | Chief Medical Officer | 8-K, 2026-05-19 |
Who leads Vistagen Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Medical Officer: Angel S. Angelov, appointed (filed 2026-05-19).
New leaders reset buying decisions — get the Full Report on Vistagen Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Medical Officer at Vistagen Therapeutics, Inc., with the record behind each one.
Find candidates like Chief Medical Officer at Vistagen Therapeutics, Inc.Every change, in the filing's words
Reported
In accordance with this plan, upon Dr. Williamson's appointment to the Board, Dr. Williamson received stock options issued under the Company's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended (the " Options "), to purchase up to 40,826 shares of the Company's common stock, par value $0.001 per share (" Common Stoc k"), at an exercise price of $0.2433 per share, an amount equal to the closing price of the Company's Common Stock on Dr. Williamson's appointment date (the " Effective Date ").
- On July 29, 2026, the Board of Directors (the "Board") of Vistagen Therapeutics, Inc. (the "Company"), upon recommendation from the Corporate Governance and Nominating Committee of the Board, unanimously approved of the appointment of Douglas J. Williamson, M.D. as a director to serve until the Company's next annual meeting of stockholders or until his successor is duly elected and qualified or until his earlier death, resignation or removal.
- Dr. Williamson will be entitled to receive compensation under the Company's Director Compensation Plan.
- The Options have a term of ten years and will vest in equal annual installments over a three-year period beginning on the one-year anniversary of the Effective Date, such that the Options will become fully vested and exercisable on the three-year anniversary of the Effective Date.
- Dr. Williamson is also entitled to annual cash compensation and equity awards under the terms of the Company's Director Compensation Plan.
- The Indemnification Agreement requires the Company to indemnify Dr. Williamson to the fullest extent permitted under Nevada law against liability that may arise by reason of his position as a director of the Company, and to advance certain expenses incurred as a result of any proceeding against him as to which he could be indemnified.
Reported
On June 16, 2026, Ms. Margaret FitzPatrick, and on June 17, 2026, Dr. Joanne Curley, each a member of the Board of Directors of Vistagen Therapeutics, Inc. (the " Company "), notified the Company of her decision not to stand for re-election at the Company's 2026 Annual Meeting of Stockholders (the " 2026 Annual Meeting ").
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers.
- Each will continue to serve as a director until the end of her term at the 2026 Annual Meeting.
Appointed: Angel S. Angelov, Chief Medical Officer
On May 18, 2026 (the " Effective Date "), Vistagen Therapeutics, Inc. (the " Company ") appointed Angel S. Angelov, M.D., MBA to serve as the Company's Chief Medical Officer.
- Dr. Angelov, age 57, served as Chief Medical Officer at Theranica, a neuromodulation therapeutics company, from October 2024 to May 2026.
- Prior to Theranica, Dr. Angelov served as Managing Director at ANG Holding from July 2023 to September 2024, as Vice President, Head of Medical Affairs, at Karuna Therapeutics, a clinical-stage biopharmaceutical company and wholly-owned subsidiary of Bristol Myers Squibb, from July 2021 to July 2023 and as Vice President, Clinical Leader for VMAT-2 Franchise and Head of Medical Affairs at Neurocrine Biosciences (Nasdaq: NBIX), a biopharmaceutical company in the neurological, endocrine, psychiatric and immunology spaces, from January 2019 to July 2021.
- He has also held clinical development and medical affairs roles at Indivior, Teva Pharmaceuticals (Nasdaq: TEVA), Novartis (NYSE: NVS), Nupathe, Inc. and Collagenex, as well as faculty positions at Thomas Jefferson University and Temple University.
- Dr. Angelov earned his M.D. from Sofia Medical University and completed his residency and fellowship training at Thomas Jefferson University.
- Dr. Angelov also earned an MBA from the Wharton School of Business.
- Dr. Angelov is Board Certified in Psychiatry, as a diplomate of the American Board of Psychiatry and Neurology, and holds an active Pennsylvania medical license.
Tools for this story
Each opens in a new tab, filled in for Vistagen Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.